Article Details

Clinical Trial Shows 71% Complete Response Rate for NXC-201 in AL Amyloidosis

Retrieved on: 2025-05-22 20:12:57

Tags for this article:

Click the tags to see associated articles and topics

Clinical Trial Shows 71% Complete Response Rate for NXC-201 in AL Amyloidosis. View article details on hiswai:

Excerpt

Immix Biopharma's ASCO abstract results for NXC-201 represent a potential breakthrough in treating relapsed/refractory AL Amyloidosis, a rare and ...

Article found on: www.stocktitan.net

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo